Why the study?
Myocardial inflammation frequently occurs in genetic cardiomyopathies, prompting a synthesis of the current state of the art to foster research toward novel mechanisms and treatment targets.
Myocardial inflammation is increasingly recognized as a key pathophysiological feature and potential therapeutic target in genetic cardiomyopathies.
Answers are grounded in this paper and cite their sources.
May support targeting inflammation in genetic cardiomyopathies; hypothesis-generating and requires prospective validation before practice change.
Over recent years, preclinical and clinical evidence has implicated myocardial inflammation (M-Infl) in the pathophysiology and phenotypes of traditionally genetic cardiomyopathies. M-Infl resembling myocarditis on imaging and histology occurs frequently as a clinical manifestation of classically genetic cardiac diseases, including dilated and arrhythmogenic cardiomyopathy. The emerging role of M-Infl in disease pathophysiology is leading to the identification of druggable targets for molecular treatment of the inflammatory process and a new paradigm in the field of cardiomyopathies. Cardiomyopathies constitute a leading cause of heart failure and arrhythmic sudden death in the young population. The aim of this review is to present, from bedside to bench, the current state of the art about the genetic basis of M-Infl in nonischemic cardiomyopathies of the dilated and arrhythmogenic spectrum in order to prompt future research towards the identification of novel mechanisms and treatment targets, with the ultimate goal of lowering disease morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
Peretto et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: